NCT00777335

Study of Panobinostat Monotherapy in Women With v-ERB-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 (HER2) Positive Locally Recurrent or Metastatic Breast Cancer

A Randomized Phase II, Open-label Multicenter Trial of Panobinostat Monotherapy in Women With HER2 Positive Locally Recurrent or Metastatic Breast Cancer

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 4 (actual)
• Sponsor: Translational Research in Oncology · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to assess the benefit of panobinostat monotherapy given either orally or i.v. to women with HER2-positive locally recurrent or metastatic breast cancer

Conditions

• Breast Cancer

Interventions

Type	Name	Description
DRUG	Panobinostat - LBH589	Solution for infusion - 25mg/5ml
DRUG	Panobinostat - LBH589	Hard gelatine capsules - 5mg and 20 mg

Timeline

• Start date: 2009-02-01
• Primary completion: 2010-03-01
• Completion: 2010-03-01
• First posted: 2008-10-22
• Last updated: 2015-11-24
• Results posted: 2012-04-10

Locations

1 site across 1 country: United States